Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy

IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex; however, the presence of IL-10 in advanced metastases and the positive correlation between serum IL-10 levels and progression of disease indicates...

Full description

Saved in:
Bibliographic Details
Published in:Immunologic research 2011-12, Vol.51 (2-3), p.170-182
Main Authors: Sato, Takami, Terai, Mizue, Tamura, Yutaka, Alexeev, Vitali, Mastrangelo, Michael J., Selvan, Senthamil R.
Format: Article
Language:English
Subjects:
Allergology
Animals
Antigen-presenting cells
Biomedical and Life Sciences
Biomedicine
Cancer
Current Immunology Research at Jefferson
Cytokines
Humans
Immunology
Immunosuppression
Immunotherapy
Immunotherapy - methods
Interleukin-10 - antagonists & inhibitors
Interleukin-10 - immunology
Internal Medicine
Medicine/Public Health
Metastasis
Molecular Targeted Therapy
Neoplasms - drug therapy
Neoplasms - immunology
Neoplasms - therapy
T-Lymphocyte Subsets - immunology
T-Lymphocytes, Regulatory - immunology
Tumor Microenvironment
Tumors
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:IL-10 is an immunomodulatory cytokine that is frequently upregulated in various types of cancer. The biological role of IL-10 in cancer is quite complex; however, the presence of IL-10 in advanced metastases and the positive correlation between serum IL-10 levels and progression of disease indicates a critical role of IL-10 in the tumor microenvironment. IL-10 has been shown to directly affect the function of antigen-presenting cells by inhibiting the expression of MHC and costimulatory molecules, which in turn induces immune suppression or tolerance. Additionally, IL-10 downregulates the expression of Th1 cytokines and induces T-regulatory responses. Taken together, a combination of IL-10 antagonism and immunostimulatory treatments such as cancer vaccines, Toll-like receptor agonists, Th1 cytokines, and chemokines would be a logical approach to enhance an antitumor immune response.
ISSN:0257-277X
1559-0755
DOI:10.1007/s12026-011-8262-6